

s (uroporphyrin OR "Chemical compounds" OR "Organic compounds" OR "Cyclic compounds" OR "Heterocyclic compounds" OR "Porphyrins" OR "Uroporp

L1 156300 (UROPORPHYRIN OR "CHEMICAL COMPOUNDS" OR "ORGANIC COMPOUNDS" OR "CYCLIC COMPOUNDS" OR "HETEROCYCLIC COMPOUNDS" OR "PORPHYRINS" OR "UROPORPHYRIN" OR "21H,23H-PORPHINE-C,C,C,2-TETRAPROPANOIC ACID, C,C,C,3-TETRAKIS(CARBOXYMETHYL)-")

s l1 and (neuron OR "Cell" OR "Body, anatomical" OR "Neuron")

L2 7289 L1 AND (NEURON OR "CELL" OR "BODY, ANATOMICAL" OR "NEURON")

s l2 and (amyotrop? or stroke or encephalitis or meningitis or neuropathy or diabet? or barre)

L3 267 L2 AND (AMYOTROP? OR STROKE OR ENCEPHALITIS OR MENINGITIS OR NEUROPATHY OR DIABET? OR BARRE)

S L3 AND 1800<=PY<=2004
24972310 1800<=PY<=2004

L4 191 L3 AND 1800<=PY<=2004

S (UROPORPHYRIN)

L6 1595 (UROPORPHYRIN)
(UROPORPHYRIN OR UROPORPHYRINS)

s l4 and l6

L7 2 L4 AND L6

991>01/11/2006

FILE 'HOME' ENTERED AT 18:12:41 ON 15 OCT 2006

=> fil hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.42

0.42

FILE 'HCAPLUS' ENTERED AT 18:13:36 ON 15 OCT 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Oct 2006 VOL 145 ISS 17

FILE LAST UPDATED: 13 Oct 2006 (20061013/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s (uroporphyrin OR "Chemical compounds" OR "Organic compounds" OR "Cyclic compounds" OR "Heterocyclic compounds" OR "Porphyrins" OR "Uroporphyrin" OR "21H,23H-Porphine-C,C,C,2-tetrapropoic acid, C,C,C,3-tetrakis(carboxymethyl) -")

1498 UROPORPHYRIN

352 UROPORPHYRINS

1595 UROPORPHYRIN

(UROPORPHYRIN OR UROPORPHYRINS)

902595 "CHEMICAL"

50855 "CHEMICALS"

945721 "CHEMICAL"

("CHEMICAL" OR "CHEMICALS")

1563934 "CHEM"

74532 "CHEMS"

1605944 "CHEM"

("CHEM" OR "CHEMS")

2227480 "CHEMICAL"

("CHEMICAL" OR "CHEM")

840337 "COMPOUNDS"

9 "COMPOUNDSSES"

840346 "COMPOUNDS"

("COMPOUNDS" OR "COMPOUNDSSES")

14060 "CHEMICAL COMPOUNDS"

("CHEMICAL" (W) "COMPOUNDS")

363872 "ORGANIC"

3797 "ORGANICS"

366317 "ORGANIC"

("ORGANIC" OR "ORGANICS")

984398 "ORG"

15288 "ORGS"

989931 "ORG"

("ORG" OR "ORGS")

1089562 "ORGANIC"

```

      ("ORGANIC" OR "ORG")
840337 "COMPOUNDS"
      9 "COMPOUNDES"
840346 "COMPOUNDS"
      ("COMPOUNDS" OR "COMPOUNDES")
80333 "ORGANIC COMPOUNDS"
      ("ORGANIC" (W) "COMPOUNDS")
309788 "CYCLIC"
      348 "CYCLICS"
309924 "CYCLIC"
      ("CYCLIC" OR "CYCLICS")
840337 "COMPOUNDS"
      9 "COMPOUNDES"
840346 "COMPOUNDS"
      ("COMPOUNDS" OR "COMPOUNDES")
      6501 "CYCLIC COMPOUNDS"
          ("CYCLIC" (W) "COMPOUNDS")
101658 "HETEROCYCLIC"
      1585 "HETEROCYCLICS"
102429 "HETEROCYCLIC"
      ("HETEROCYCLIC" OR "HETEROCYCLICS")
840337 "COMPOUNDS"
      9 "COMPOUNDES"
840346 "COMPOUNDS"
      ("COMPOUNDS" OR "COMPOUNDES")
      31775 "HETEROCYCLIC COMPOUNDS"
          ("HETEROCYCLIC" (W) "COMPOUNDS")
24933 "PORPHYRINS"
      1498 "UROPORPHYRIN"
      352 "UROPORPHYRINS"
      1595 "UROPORPHYRIN"
          ("UROPORPHYRIN" OR "UROPORPHYRINS")
      1449 "21H"
      1350 "23H"
      4325 "PORPHINE"
      370 "PORPHINES"
      4433 "PORPHINE"
          ("PORPHINE" OR "PORPHINES")
3526483 "C"
3526483 "C"
3526483 "C"
8909907 "2"
      13 "TETRAPROPANOIC"
4227111 "ACID"
1544524 "ACIDS"
4722618 "ACID"
      ("ACID" OR "ACIDS")
3526483 "C"
3526483 "C"
3526483 "C"
6707722 "3"
      42399 "TETRAKIS"
      35233 "CARBOXYMETHYL"
          3 "CARBOXYMETHYLS"
      35233 "CARBOXYMETHYL"
          ("CARBOXYMETHYL" OR "CARBOXYMETHYLS")
      0 "21H,23H-PORPHINE-C,C,C,2-TETRAPROPANOIC ACID, C,C,C,3-TETRAKIS(
CARBOXYMETHYL) - "
          ("21H" (W) "23H" (W) "PORPHINE" (W) "C" (W) "C" (W) "C" (W) "2" (W) "TETRAPR
OPANOIC" (W) "ACID" (W) "C" (W) "C" (W) "C" (W) "3" (W) "TETRAKIS" (W) "CARB
OXYMETHYL")
L1 156300 (UROPORPHYRIN OR "CHEMICAL COMPOUNDS" OR "ORGANIC COMPOUNDS" OR
"CYCLIC COMPOUNDS" OR "HETEROCYCLIC COMPOUNDS" OR "PORPHYRINS"

```

OR "UROPORPHYRIN" OR "21H,23H-PORPHINE-C,C,C,2-TETRAPROPANOIC
ACID, C,C,C,3-TETRAKIS(CARBOXYMETHYL) -")

=> s 11 and (neuron OR "Cell" OR "Body, anatomical" OR "Neuron")

97313 NEURON
147581 NEURONS
181074 NEURON
(NEURON OR NEURONS)
2122094 "CELL"
1854793 "CELLS"
2804556 "CELL"
("CELL" OR "CELLS")
584780 "BODY"
116815 "BODIES"
668373 "BODY"
("BODY" OR "BODIES")
41988 "ANATOMICAL"
6218 "BODY, ANATOMICAL"
("BODY" (W) "ANATOMICAL")
97313 "NEURON"
147581 "NEURONS"
181074 "NEURON"
("NEURON" OR "NEURONS")

L2 7289 L1 AND (NEURON OR "CELL" OR "BODY, ANATOMICAL" OR "NEURON")

=> s 12 and (amyotrop? or stroke or encephalitis or meningitis or neuropathy or diabet? or barre)

5921 AMYOTROP?
30340 STROKE
2165 STROKES
31644 STROKE
(STROKE OR STROKES)
7938 ENCEPHALITIS
1 ENCEPHALITISES
7938 ENCEPHALITIS
(ENCEPHALITIS OR ENCEPHALITISES)
5840 MENINGITIS
11982 NEUROPATHY
1458 NEUROPATHIES
12520 NEUROPATHY
(NEUROPATHY OR NEUROPATHIES)
131409 DIABET?
1494 BARRE
10 BARRES
1504 BARRE
(BARRE OR BARRES)

L3 267 L2 AND (AMYOTROP? OR STROKE OR ENCEPHALITIS OR MENINGITIS OR
NEUROPATHY OR DIABET? OR BARRE)

=> S L3 AND 1800<=PY<=2004

24972310 1800<=PY<=2004

L4 191 L3 AND 1800<=PY<=2004

=> s 14 and uroporphyrin/th
'TH' IS NOT A VALID FIELD CODE
0 UROPORPHYRIN/TH

L5 0 L4 AND UROPORPHYRIN/TH

=> S (UROPORPHYRIN)

1498 UROPORPHYRIN
352 UROPORPHYRINS

L6 1595 (UROPORPHYRIN)
(UROPORPHYRIN OR UROPORPHYRINS)

991>01/11/2006

=> s 14 and 16
L7 2 L4 AND L6

=> d 17 ibib abs hitstr

L7 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:739963 HCAPLUS <<LOGINID::20061015>>
DOCUMENT NUMBER: 141:236687
TITLE: Method to treat patients with amyotrophic
lateral sclerosis and the like
INVENTOR(S): Rooney, Roberta Nora Malone
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 12 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004176344	A1	20040909	US 2004-708991	20040406 <--
PRIORITY APPLN. INFO.:			US 2004-708991	20040406
AB The hepatically produced isomers, URO I and URO III, are neuroprotectants capable of halting or mitigating the nervous system destruction in common neurol. disorders. URO I protects neurons of the central nervous system from damage that would otherwise ensue from the neurotoxicity associated with the hepatic heme porphyrin precursors, delta-aminolevulinic acid and porphobilinogen. A method is disclosed to increase URO I to treat amyotrophic lateral sclerosis (ALS), stroke, encephalitis, meningitis, spinal cord injury and hereditary biochem. multiple sclerosis. Increases of URO III are also used to protect neurons in the peripheral nervous system in disorders including acute immunodeficiency syndrome (AIDS) related neuropathy, Guillaine-Barre syndrome and diabetic neuropathy.				

=> d 17 ibib abs hitstr

L7 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:739963 HCAPLUS <<LOGINID::20061015>>
DOCUMENT NUMBER: 141:236687
TITLE: Method to treat patients with amyotrophic
lateral sclerosis and the like
INVENTOR(S): Rooney, Roberta Nora Malone
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 12 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004176344	A1	20040909	US 2004-708991	20040406 <--
PRIORITY APPLN. INFO.:			US 2004-708991	20040406
AB The hepatically produced isomers, URO I and URO III, are neuroprotectants capable of halting or mitigating the nervous system destruction in common neurol. disorders. URO I protects neurons of the central nervous system from damage that would otherwise ensue from the				

neurotoxicity associated with the hepatic heme porphyrin precursors, delta-aminolevulinic acid and porphobilinogen. A method is disclosed to increase URO I to treat amyotrophic lateral sclerosis (ALS), stroke, encephalitis, meningitis, spinal cord injury and hereditary biochem. multiple sclerosis. Increases of URO III are also used to protect neurons in the peripheral nervous system in disorders including acute immunodeficiency syndrome (AIDS) related neuropathy, Guillaine-Barre syndrome and diabetic neuropathy.

=> d 17 2 ibib abs hitstr

L7 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1950:15629 HCAPLUS <<LOGINID::20061015>>

DOCUMENT NUMBER: 44:15629

ORIGINAL REFERENCE NO.: 44:3122f-i,3123a-d

TITLE: Zinc in the mammalian organism, with particular reference to carbonic anhydrase

AUTHOR(S): Vallee, B. L.; Altschule, M. D.

CORPORATE SOURCE: Massachusetts Inst. Technol., Cambridge

SOURCE: Physiological Reviews (1949), 29, 370-88

CODEN: PHREA7; ISSN: 0031-9333

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB Zn is found in organs of vertebrates in amts. ranging from 10 to 200 γ /g. In nucleated erythrocytes the nuclei contain about 3 times as much Zn as the cytoplasm. The ratio of erythrocyte Zn/plasma Zn is 0.6 in fish, 1.6 in frog, 2.3 in turtle, to 3.2 in goose; the ratio increases with phylogenetic evolution. Ram semen sperm contains 0.70 and plasma 0.28 mg. % (semen). Human intake is 10-15 mg./day, and most is excreted in the feces. Woman's milk contains about 2 mg./kg. Zn-deficient rats grow 1/3 as fast as controls; their fur softens and turns gray in 6-7 weeks; they require about 150% as many rations as Zn-fed controls to gain 1 g. in weight. Forty γ Zn/day is enough to remove signs of Zn deficiency which develop on 22 γ /day. Blood sugar and liver glycogen are normal in the Zn-deficient rats, but the plasma-protein is subnormal. Glucose-tolerance curves and the blood N reveal abnormalities in metabolism. Pancreatic amylase and proteinase are lowered in Zn-deficient rats, and this can not be restored by addition of Zn in vitro or in vivo. No changes are observed in bone phosphatase but intestinal phosphatase is decreased. No striking change is noted in carbonic anhydrase (I). Blood uric acid is doubled and uricase activity is normal. Intravenous Zn gluconate (2 mg./kg.) is well tolerated by dog or man but 4 mg./kg. is not. The effect of fed Zn is discussed. The work on relation of Zn to cancer is regarded as invalid. Leukemic leucocytes contain about 1/10 the normal amount of Zn, but this is not influenced by injecting Zn. Neoplastic cells may have a Zn distribution different from the normal. No significant difference apparently exists between the Zn content of normal and diabetic pancreases. In pernicious anemia the erythrocyte Zn is elevated, but after 60-70 days of liver therapy it returns to normal. There is no evidence that insulin and Zn must combine in vivo to form an active compound, and the Zn content of pancreas exceeds that necessary for insulin activation. There is activation of hypophyseal gonadotropic exts. by Zn as well as activation of the follicle-stimulating and luteinizing hormones. In acute, intermittent porphyria a Zn uroporphyrin is found in urine and feces. A Zn coproporphyrin has been described. The presence of Zn in uricase, kidney phosphatase, and zymohexase is doubtful or has been disproved; I contains Zn as an active component. I has a mol. weight, of approx. 30, 000, isoelec. point about 5.6 and is reversibly inactivated by oxidizing agents or irreversibly by heat. I is confined to the erythrocytes and is about 1% of the hemoglobin content. In hemorrhage or nutritional anemia I decreases parallel to the

decrease in hematocrit value or hemoglobin concentration In pernicious anemia I is practically normal. In polycythemia vera or in secondary polycythemia the blood I is increased. Both in anemia and in polycythemia there is a close parallelism between I activity and erythrocyte Zn concentration 192 references.

=> E ROONEY R/AU 25

E1	1	ROONEY PIERCE/AU
E2	2	ROONEY PIERCE A/AU
E3	1 -->	ROONEY R/AU
E4	1	ROONEY R A/AU
E5	40	ROONEY R C/AU
E6	1	ROONEY R J/AU
E7	1	ROONEY R N/AU
E8	5	ROONEY REGINA/AU
E9	10	ROONEY REGINA D/AU
E10	3	ROONEY REGINA M/AU
E11	3	ROONEY RICHARD T/AU
E12	1	ROONEY RICK/AU
E13	2	ROONEY ROBERT/AU
E14	16	ROONEY ROBERT J/AU
E15	1	ROONEY ROBERT JOSEPH/AU
E16	3	ROONEY ROBERT LAMBIE/AU
E17	5	ROONEY ROBERT P/AU
E18	1	ROONEY ROBERT PATRICK GRAHAM/AU
E19	1	ROONEY ROBERTA NORA MALONE/AU
E20	4	ROONEY RONALD C/AU
E21	4	ROONEY ROSEMARY T/AU
E22	4	ROONEY S/AU
E23	10	ROONEY S A/AU
E24	3	ROONEY S M/AU
E25	1	ROONEY SALLY C/AU

=> S (E3 OR E4 OR E5 OR E6 OR E7 OR E8 OR E9 OR E10 OR E11 OR E12 OR E13 OR E14 OR E15 OR E16 OR E17 OR E18 OR E19 OR E20 OR E21) AND (UROPORPHYRIN)

1	"ROONEY R"/AU
1	"ROONEY R A"/AU
40	"ROONEY R C"/AU
1	"ROONEY R J"/AU
1	"ROONEY R N"/AU
5	"ROONEY REGINA"/AU
10	"ROONEY REGINA D"/AU
3	"ROONEY REGINA M"/AU
3	"ROONEY RICHARD T"/AU
1	"ROONEY RICK"/AU
2	"ROONEY ROBERT"/AU
16	"ROONEY ROBERT J"/AU
1	"ROONEY ROBERT JOSEPH"/AU
3	"ROONEY ROBERT LAMBIE"/AU
5	"ROONEY ROBERT P"/AU
1	"ROONEY ROBERT PATRICK GRAHAM"/AU
1	"ROONEY ROBERTA NORA MALONE"/AU
4	"ROONEY RONALD C"/AU
4	"ROONEY ROSEMARY T"/AU
1498	UROPORPHYRIN
352	UROPORPHYRINS
1595	UROPORPHYRIN

(UROPORPHYRIN OR UROPORPHYRINS)

L8 1 ("ROONEY R"/AU OR "ROONEY R A"/AU OR "ROONEY R C"/AU OR "ROONEY R J"/AU OR "ROONEY R N"/AU OR "ROONEY REGINA"/AU OR "ROONEY REGINA D"/AU OR "ROONEY REGINA M"/AU OR "ROONEY RICHARD T"/AU OR "ROONEY RICK"/AU OR "ROONEY ROBERT"/AU OR "ROONEY ROBERT J"/AU OR "ROONEY ROBERT JOSEPH"/AU OR "ROONEY ROBERT LAMBIE"/AU OR "ROONEY ROBERT P"/AU OR "ROONEY ROBERT PATRICK GRAHAM"/AU OR "ROONEY ROBERTA NORA MALONE"/AU OR "ROONEY RONALD C"/AU OR "ROONEY ROSEMARY T"/AU) AND

(UROPORPHYRIN)

=> S (E3 OR E4 OR E5 OR E6 OR E7 OR E8 OR E9 OR E10 OR E11 OR E12 OR E13 OR E14 OR E15 OR E16 OR E17 OR E18 OR E19 OR E20 OR E21) AND (BLOOD)

1 "ROONEY R"/AU
 1 "ROONEY R A"/AU
 40 "ROONEY R C"/AU
 1 "ROONEY R J"/AU
 1 "ROONEY R N"/AU
 5 "ROONEY REGINA"/AU
 10 "ROONEY REGINA D"/AU
 3 "ROONEY REGINA M"/AU
 3 "ROONEY RICHARD T"/AU
 1 "ROONEY RICK"/AU
 2 "ROONEY ROBERT"/AU
 16 "ROONEY ROBERT J"/AU
 1 "ROONEY ROBERT JOSEPH"/AU
 3 "ROONEY ROBERT LAMBIE"/AU
 5 "ROONEY ROBERT P"/AU
 1 "ROONEY ROBERT PATRICK GRAHAM"/AU
 1 "ROONEY ROBERTA NORA MALONE"/AU
 4 "ROONEY RONALD C"/AU
 4 "ROONEY ROSEMARY T"/AU
 1266300 BLOOD
 1229 BLOODS
 1266436 BLOOD

(BLOOD OR BLOODS)

L9 7 ("ROONEY R"/AU OR "ROONEY R A"/AU OR "ROONEY R C"/AU OR "ROONEY R J"/AU OR "ROONEY R N"/AU OR "ROONEY REGINA"/AU OR "ROONEY REGINA D"/AU OR "ROONEY REGINA M"/AU OR "ROONEY RICHARD T"/AU OR "ROONEY RICK"/AU OR "ROONEY ROBERT"/AU OR "ROONEY ROBERT J"/AU OR "ROONEY ROBERT JOSEPH"/AU OR "ROONEY ROBERT LAMBIE"/AU OR "ROONEY ROBERT P"/AU OR "ROONEY ROBERT PATRICK GRAHAM"/AU OR "ROONEY ROBERTA NORA MALONE"/AU OR "ROONEY RONALD C"/AU OR "ROONEY ROSEMARY T"/AU) AND (BLOOD)

=> S (E3 OR E4 OR E5 OR E6 OR E7 OR E8 OR E9 OR E10 OR E11 OR E12 OR E13 OR E14 OR E15 OR E16 OR E17 OR E18 OR E19 OR E20 OR E21) AND (BLOOD BRAIN)

1 "ROONEY R"/AU
 1 "ROONEY R A"/AU
 40 "ROONEY R C"/AU
 1 "ROONEY R J"/AU
 1 "ROONEY R N"/AU
 5 "ROONEY REGINA"/AU
 10 "ROONEY REGINA D"/AU
 3 "ROONEY REGINA M"/AU
 3 "ROONEY RICHARD T"/AU
 1 "ROONEY RICK"/AU
 2 "ROONEY ROBERT"/AU
 16 "ROONEY ROBERT J"/AU
 1 "ROONEY ROBERT JOSEPH"/AU
 3 "ROONEY ROBERT LAMBIE"/AU
 5 "ROONEY ROBERT P"/AU
 1 "ROONEY ROBERT PATRICK GRAHAM"/AU
 1 "ROONEY ROBERTA NORA MALONE"/AU
 4 "ROONEY RONALD C"/AU
 4 "ROONEY ROSEMARY T"/AU
 1266300 BLOOD
 1229 BLOODS
 1266436 BLOOD

(BLOOD OR BLOODS)

529720 BRAIN
 24604 BRAINS
 532411 BRAIN

(BRAIN OR BRAINS)

17634 BLOOD BRAIN

(BLOOD(W) BRAIN)

L10 1 ("ROONEY R"/AU OR "ROONEY R A"/AU OR "ROONEY R C"/AU OR "ROONEY R J"/AU OR "ROONEY R N"/AU OR "ROONEY REGINA"/AU OR "ROONEY REGINA D"/AU OR "ROONEY REGINA M"/AU OR "ROONEY RICHARD T"/AU OR "ROONEY RICK"/AU OR "ROONEY ROBERT"/AU OR "ROONEY ROBERT J"/AU OR "ROONEY ROBERT JOSEPH"/AU OR "ROONEY ROBERT LAMBIE"/AU OR "ROONEY ROBERT P"/AU OR "ROONEY ROBERT PATRICK GRAHAM"/AU OR "ROONEY ROBERTA NORA MALONE"/AU OR "ROONEY RONALD C"/AU OR "ROONEY ROSEMARY T"/AU) AND
(BLOOD BRAIN)

=> s 19

1 "ROONEY R"/AU
1 "ROONEY R A"/AU
40 "ROONEY R C"/AU
1 "ROONEY R J"/AU
1 "ROONEY R N"/AU
5 "ROONEY REGINA"/AU
10 "ROONEY REGINA D"/AU
3 "ROONEY REGINA M"/AU
3 "ROONEY RICHARD T"/AU
1 "ROONEY RICK"/AU
2 "ROONEY ROBERT"/AU
16 "ROONEY ROBERT J"/AU
1 "ROONEY ROBERT JOSEPH"/AU
3 "ROONEY ROBERT LAMBIE"/AU
5 "ROONEY ROBERT P"/AU
1 "ROONEY ROBERT PATRICK GRAHAM"/AU
1 "ROONEY ROBERTA NORA MALONE"/AU
4 "ROONEY RONALD C"/AU
4 "ROONEY ROSEMARY T"/AU
1266300 BLOOD
1229 BLOODS
1266436 BLOOD

(BLOOD OR BLOODS)

L11 7 ("ROONEY R"/AU OR "ROONEY R A"/AU OR "ROONEY R C"/AU OR "ROONEY R J"/AU OR "ROONEY R N"/AU OR "ROONEY REGINA"/AU OR "ROONEY REGINA D"/AU OR "ROONEY REGINA M"/AU OR "ROONEY RICHARD T"/AU OR "ROONEY RICK"/AU OR "ROONEY ROBERT"/AU OR "ROONEY ROBERT J"/AU OR "ROONEY ROBERT JOSEPH"/AU OR "ROONEY ROBERT LAMBIE"/AU OR "ROONEY ROBERT P"/AU OR "ROONEY ROBERT PATRICK GRAHAM"/AU OR "ROONEY ROBERTA NORA MALONE"/AU OR "ROONEY RONALD C"/AU OR "ROONEY ROSEMARY T"/AU) AND (BLOOD)

=> d scan

L11 7 ANSWERS HCAPLUS COPYRIGHT 2006 ACS on STN
CC 9-4 (Biochemical Methods)
TI Determination of bismuth in blood and urine
ST bismuth detn blood urine
IT Blood analysis
Urine analysis
(bismuth determination in, atomic-adsorption spectrophotometric)
IT 7440-69-9, analysis
RL: ANT (Analyte); ANST (Analytical study)
(determination of, in blood and urine, atomic-adsorption spectrophotometric)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):6

L11 7 ANSWERS HCAPLUS COPYRIGHT 2006 ACS on STN
CC 1-1 (Pharmacology)
TI A sensitive radioimmunoassay, combined with solid-phase extraction, for

the sub-nanogram per mL determination of ondansetron in human plasma

ST ondansetron detn RIA plasma

IT Blood analysis
(ondansetron determination by RIA combined with solid-phase extraction in)

IT 110708-17-3 126671-71-4 126702-17-8 154753-85-2
RL: ANT (Analyte); ANST (Analytical study)
(determination of, as ondansetron metabolite in plasma by RIA combined with solid-phase extraction)

IT 99614-02-5, Ondansetron 99614-58-1 99614-60-5
RL: ANT (Analyte); ANST (Analytical study)
(determination of, in plasma by RIA combined with solid-phase extraction)

IT 154753-86-3D, conjugates with thyroglobulin
RL: ANST (Analytical study)
(immunogen, in determination of ondansetron in plasma by RIA combined with solid-phase extraction)

IT 154753-84-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for RIA)

L11 7 ANSWERS HCAPLUS COPYRIGHT 2006 ACS on STN

IC ICM A61K031-555
ICS A61K031-409

INCL 514185000; 514410000

CC 1-11 (Pharmacology)
Section cross-reference(s): 63

TI Method to treat patients with amyotrophic lateral sclerosis and the like

ST serum neuroprotectant UROIII UROI infusion amyotrophic lateral sclerosis

IT AIDS (disease)
(- related neuropathy; method to treat patients with amyotrophic lateral sclerosis and the like)

IT Porphyrins
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(-associated neuron damage; method to treat patients with amyotrophic lateral sclerosis and the like)

IT Blood-brain barrier
(-weakening drugs; method to treat patients with amyotrophic lateral sclerosis and the like)

IT Nervous system, disease
(Guillain-Barre syndrome; method to treat patients with amyotrophic lateral sclerosis and the like)

IT Nervous system, disease
(amyotrophic lateral sclerosis; method to treat patients with amyotrophic lateral sclerosis and the like)

IT Drug delivery systems
(by shunt or stent directly into the brain; method to treat patients with amyotrophic lateral sclerosis and the like)

IT Nerve, disease
(diabetic neuropathy; method to treat patients with amyotrophic lateral sclerosis and the like)

IT Multiple sclerosis
(hereditary biochem.; method to treat patients with amyotrophic lateral sclerosis and the like)

IT Drug delivery systems
(infusions; method to treat patients with amyotrophic lateral sclerosis and the like)

IT Drug delivery systems
(injections, i.v.; method to treat patients with amyotrophic lateral sclerosis and the like)

IT Nerve, disease
(injury; method to treat patients with amyotrophic lateral sclerosis and the like)

IT Drug delivery systems
(intrathecal; method to treat patients with amyotrophic lateral

sclerosis and the like)

IT Blood
 Blood serum
 Blood-brain barrier
 Central nervous system
 Encephalitis
 Human
 Liver
 Meningitis
 Nervous system, disease
 Peripheral nervous system
 Urine analysis
 (method to treat patients with amyotrophic lateral sclerosis and the like)

IT Enzymes, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (method to treat patients with amyotrophic lateral sclerosis and the like)

IT Injury
 (neuronal; method to treat patients with amyotrophic lateral sclerosis and the like)

IT Nerve, disease
 (neuropathy, acute immunodeficiency syndrome-related; method to treat patients with amyotrophic lateral sclerosis and the like)

IT Cytoprotective agents
 Nervous system agents
 (neuroprotective agents; method to treat patients with amyotrophic lateral sclerosis and the like)

IT Drug delivery systems
 (olfactory (nasal); method to treat patients with amyotrophic lateral sclerosis and the like)

IT Drug delivery systems
 (oral; method to treat patients with amyotrophic lateral sclerosis and the like)

IT Absorption
 (osmotic; method to treat patients with amyotrophic lateral sclerosis and the like)

IT Nervous system, disease
 (peripheral; method to treat patients with amyotrophic lateral sclerosis and the like)

IT Medical goods
 (stents; method to treat patients with amyotrophic lateral sclerosis and the like)

IT Brain, disease
 (stroke; method to treat patients with amyotrophic lateral sclerosis and the like)

IT 106-60-5 487-90-1, Porphobilinogen
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (method to treat patients with amyotrophic lateral sclerosis and the like)

IT 9024-70-8, Uroporphyrinogen decarboxylase 9036-37-7, Aminolevulinic acid dehydratase 9074-91-3, Porphobilinogen deaminase 35465-57-7, Uroporphyrinogen 37293-37-1, Co-protoporphyrinogen 37340-55-9, Uroporphyrinogen III synthase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (method to treat patients with amyotrophic lateral sclerosis and the like)

IT 607-14-7, Uroporphyrin I 18273-06-8, Uroporphyrin III 26316-36-9D, Uroporphyrin, isomers
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (method to treat patients with amyotrophic lateral sclerosis and the like)

IT 7439-89-6, Iron, biological studies
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (method to treat patients with amyotrophic lateral sclerosis and the like)

L11 7 ANSWERS HCAPLUS COPYRIGHT 2006 ACS on STN
 CC 79-6 (Inorganic Analytical Chemistry)
 TI Use of sodium borohydride for cold-vapor atomic-absorption determination of trace amounts of inorganic mercury
 ST mercury detn borohydride redn; paint mercury detn; food mercury detn; plant mercury detn; blood mercury detn; urine mercury detn; alloy mercury detn
 IT 16940-66-2
 RL: ANST (Analytical study)
 (as reducing agent, in determination of mercury by cold-vapor atomic absorption spectrophotometry)

IT 7439-97-6, analysis
 RL: ANT (Analyte); ANST (Analytical study)
 (determination of, sodium borohydride reductant in cold-vapor atomic absorption spectrophotometric)

L11 7 ANSWERS HCAPLUS COPYRIGHT 2006 ACS on STN
 CC 79-0 (Inorganic Analytical Chemistry)
 Section cross-reference(s): 4, 59
 TI The determination of trace toxic metals in industrial hygiene by polarographic methods
 ST review polarog trace metal detn; industrial hygiene polarog analysis review; blood analysis metal polarog review; urine analysis metal polarog review; air filter analysis metal review
 IT Polarography
 (in determination of trace metals in biol. and environmental samples and in industrial hygiene)

IT Air analysis
 (trace metal determination in filters in, by polarog.)

IT Blood analysis
 Urine analysis
 (trace metal determination in, polarog.)

IT Hygiene
 (industrial, trace metals in, determination of, by polarog.)

IT Trace elements
 RL: ANT (Analyte); ANST (Analytical study)
 (metals, determination of, in biol. and environmental samples and in industrial hygiene, polarog.)

L11 7 ANSWERS HCAPLUS COPYRIGHT 2006 ACS on STN
 CC 1-1 (Pharmacology)
 Section cross-reference(s): 64
 TI Application of the scintillation proximity assay technique to the determination of drugs
 ST drug detn RIA scintillation proximity assay; ranitidine detn plasma scintillation proximity assay
 IT Blood analysis
 (ranitidine determination in human, by scintillation proximity assay)

IT Pharmaceutical analysis
 (scintillation proximity assay technique in)

IT Immunoassay
 (radioimmunoassay, scintillation proximity assay technique in, drugs determination by)

IT 66357-35-5, Ranitidine
 RL: ANT (Analyte); ANST (Analytical study)
 (determination of, in human blood plasma, by scintillation proximity assay)

991>01/11/2006

L11 7 ANSWERS HCAPLUS COPYRIGHT 2006 ACS on STN
CC 60 (Biochemical Methods)
TI Applications of polarography in physiological analysis
IT Blood
 (analysis, determination of Co and Pb, polarography and)
IT Polarography
 (in analysis (physiological))
IT 7439-92-1, Lead
 (analysis, determination in blood and urine, polarography and)
IT 7440-48-4, Cobalt
 (analysis, determination in blood, polarography and)
IT 7429-90-5, Aluminum
 (analysis, determination in urine, polarography in relation to)

ALL ANSWERS HAVE BEEN SCANNED

=> fil stnguide

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
71.47	71.89

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-2.25	-2.25

CA SUBSCRIBER PRICE

FILE 'STNGUIDE' ENTERED AT 18:28:44 ON 15 OCT 2006

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Oct 13, 2006 (20061013/UP).